Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says

By Jamie Gumbrecht, CNN (CNN) — An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, Novo Nordisk said Monday. In two Phase 3 trials of more than 3,800 adults receiving standard care for Alzheimer’s, the company evaluated whether